Study #2015-1040
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) with Dasatinib and Venetoclax: A Phase II Study
MD Anderson Study Status
Enrolling
Treatment Agent
Dasatinib, Venetoclax
Description
This phase II trial studies how well dasatinib and venetoclax work in treating patients with Philadelphia chromosome positive or BCR-ABL1 positive early chronic phase chronic myelogenous leukemia. Dasatinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Information and next steps
Disease:
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Study phase:
II
Physician name:
Ghayas Issa
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.